Table 3 Reasons to discontinue anti-TNF treatment in JIA patients taking etanercept or infliximab during a 4-year follow-up
Etanercept n  =  105Infliximab n  =  104Total n  =  209p Value*
Adverse events, n (%)7 (7)23 (22)30 (14)0.002
Inefficacy, n (%)29 (28)21 (20)50 (24)0.445
Inactive disease, n (%)10 (10)17 (16)27 (13)0.068
  • *Difference between two treatments based on log-rank test. JIA, juvenile idiopathic arthritis; TNF, tumour necrosis factor.